Drug Profile
Sufentanil transdermal - NAL Pharma
Alternative Names: NAL 1241; Sufentanyl - NAL PharmaLatest Information Update: 06 Nov 2021
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Amides; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer pain
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Cancer-pain in Unknown (Transdermal, Patch)
- 26 Aug 2016 Chemical structure information added
- 11 Aug 2016 Sufentanil transdermal - NAL Pharma is available for licensing as of 11 Aug 2016. http://www.nalpharma.com/licensing.php?id=4&lang=en